Focus:
Cardiovascular
-
5 April 2019 whitepapers
The Odour of Blood
Blood is an extremely complex mixture and the number of different components that can be detected in its aroma owes as much to the separating ability and sensitivity of the...
-
25 March 2019 Comment
Paclitaxel-coated devices under close watch by FDA following long-term, follow-up data
Minimally invasive interventions for treating peripheral artery disease (PAD) are growing as they continue to demonstrate better patient outcomes compared to pharmaceutical treatment and open surgery.
-
14 March 2019 News
Stanford researchers identify existing drug can mitigate chemotherapy side effects
Researchers from the Stanford University School of Medicine have discovered that AMPK activators, which include metformin for type 2 diabetes, could mitigate the cardiac side effects of chemotherapy drug trastuzumab.
-
13 March 2019 Comment
Top drivers behind cardiovascular market growth by 2024
Only two pipeline agents in the cardiovascular space are expected to reach blockbuster status (with sales over $1 billion) by 2024.
-
4 March 2019 News
FDA announces another carcinogenic impurity in ARB blood pressure drugs
The US Food and Drug Administration (FDA) has revealed that a third impurity has been found in generic angiotensin II receptor blocker (ARB) drugs indicated for blood pressure and heart...
-
28 February 2019 News
Novartis and Blackstone Life launch new firm Anthos Therapeutics
Novartis and private investment platform Blackstone Life Sciences have launched a new biopharmaceutical company Anthos Therapeutics focused on targeted therapies for cardiovascular diseases.
-
25 February 2019 Digital Disruption
Novartis exercises rights to Ionis’ CV drug TQJ230
Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy, from Akcea Therapeutics’ affiliate Ionis...
-
25 February 2019 News
AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patients
Global pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse cardiovascular events, in the...
-
13 February 2019 Analysis
National Heart Month: how can you heal a broken heart?
February is National Heart Month in the US and the US, which focuses on raising awareness of heart disease. Often caused by emotional distress, takotsubo cardiomyopathy is a rare heart...
-
11 February 2019 News
Regeneron and Sanofi cut US list price of Praluent
Regeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%.